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Sepsis is a major cause of death worldwide, not least 
because complex interventions need to be provided 
within a short window of opportunity. Evidence-based 
guidelines for the treatment of sepsis are therefore wel-
come, providing a common ground for all clinicians 
involved in decision-making regardless of their expertise. 
Such guidelines should therefore serve as an overarch-
ing reference document. As previously stated, ‘Guide-
lines are the product of an explicit, systematic approach 
to the evaluation and synthesis of available information 
on a particular clinical topic. They are not a compilation 
of truths, but are a summary of what is accepted by the 
authors as the best available evidence at that time’ [1].
As the evidence base evolves over time, the new Sur-
viving Sepsis Campaign (SSC) guidelines [2] are timely 
and important. We appreciate the tremendous amount 
of time invested by the experts who formulated the new 
guidelines to provide the intensive care community with 
a clear and comprehensive manuscript. We also recog-
nize the challenge of providing evidence-based guidelines 
when the strength of evidence available to direct recom-
mendations is limited. Indeed, the large majority of rand-
omized, controlled trials (RCTs) performed over the last 
three decades in intensive care medicine, including those 
in sepsis, have shown no significant beneficial effect of 
the tested intervention on outcomes [3]. At face value, 
this may simply suggest that the myriad of interventions 
that have been tested are all ineffective. However, it is 
more likely that subsets of patients who benefit from spe-
cific treatments have yet to be identified. The often broad 
patient inclusion criteria could easily lead to dilution of 
positive findings by non-responders, or to positive effects 
in some patients being offset by harm in others [4]. This 
treatment effect heterogeneity has been clearly indicated 
in many trials (for example [5–8]).
The most severely ill patients usually suffer less from 
a single condition than from a complex physiologi-
cal imbalance that defies specific disease definitions. 
Management that strictly adheres to guidelines may 
not necessarily be the best option. However, personal-
izing management of these patients mandates that  the 
treating clinician appreciates the clinical implications 
of the underlying disease(s) and individual host factors 
(chronic health status, physiology, and physiological 
reserves). Additionally, the individual response to inter-
ventions must be closely monitored and, depending on 
that response and whether or not the pre-set goal of that 
intervention has been achieved, the clinician can then 
decide to maintain or alter the intervention accordingly. 
We fully acknowledge this is demanding in resources, 
time, personnel, and bedside expertise. It is more con-
venient and less labor-intensive to adopt a generalized 
approach, yet customization is surely the underlying 
foundation of intensive care. When we forget the funda-
mental importance of individualized management, the 
ultimate result is that few interventions improve mean-
ingful patient outcomes, especially mortality [3]. We 
Open Access
*Correspondence:  jlvincent@intensive.org
1 Department of Intensive Care, Erasme Hospital, Université Libre de 
Bruxelles, 1070 Brussels, Belgium
Full list of author information is available at the end of the article
Page 2 of 4Vincent et al. Critical Care          (2021) 25:397 
must acknowledge and embrace natural (patho) physi-
ological variability; sepsis is no exception to this rule. 
Sepsis encompasses a huge spectrum of clinical situa-
tions in terms of the type of patient involved, the clinical 
presentation and the response to treatment. This variabil-
ity should serve to direct clinical management, enabling 
the clinician to adapt “recommended” care according to 
the specific needs of that patient. As David Sackett, the 
Table 1 Twenty recommendations to individualize interventions in the early resuscitation of patients with sepsis
1. We recommend individualizing the timing of ICU admission. It should ideally be within minutes in severely ill patients but can be less urgent in less 
severe cases. No time limit is applicable for all patients. The decision may be influenced by the level of care available within ward areas and by ICU 
bed availability and, of course, by the physiological status and reserve of the patient
2. We recommend individualizing the decision to admit to the ICU. Many patients develop sepsis at the end of their life. Patients with palliative care 
orders and treatment escalation plans that preclude advanced organ support should generally not be admitted
3. We recommend individualizing the timing of antibiotic therapy. Administration should be prompt in the presence of septic shock but less urgent 
in less severe cases, enabling more time to perform investigations, confirm the diagnosis and likely source, and seek expert advice
4. We recommend individualizing the need for and timing of tracheal intubation, based on careful clinical assessment, including level of conscious‑
ness, respiratory rate and work of breathing, hemodynamic status, and assessment of gas exchange. Delaying tracheal intubation may lead to 
respiratory and even cardiac arrest, with dire consequences, yet premature use of invasive mechanical ventilation can expose the patient to 
ventilator‑induced lung injury, distant organ complications, and increased risk of nosocomial lung infection
5. We recommend individualizing respiratory settings in mechanically ventilated patients, including driving pressure, tidal volume and level of posi‑
tive end‑expiratory pressure (PEEP), aiming at the lowest possible mechanical power. PEEP could be adjusted to lung recruitment capacity
6. We recommend individualizing oxygenation targets, taking oxygen delivery into account. Exposure to high  PaO2 levels may be associated with 
worse outcomes, except perhaps in necrotizing infections. Extreme oxygenation values (too conservative or too liberal) should generally be 
avoided
7. We recommend individualizing sedation therapies, recognizing that many septic patients need little or even no sedation. Tracheal intubation per 
se is not a sufficient indication for administration of sedative agents. Sedative agents reduce vascular tone and myocardial contractility, and may 
also alter immune function
8. We recommend individualizing initial fluid resuscitation. No single formula can be applied to all patients, as fluid requirements vary substantially 
(depending on the source of sepsis and preexisting cardiovascular function). This is particularly true for the suggestion to give at least 30 mL/kg 
of fluid within the first 3 h. A young patient without comorbidities is more likely to tolerate administration of a large volume of fluid than a fragile 
elderly patient with severe cardiac or renal disease
9. We recommend individualizing fluid therapy using dynamic challenges. Assessment of pulse pressure variation (PPV) or stroke volume variation 
(SVV) is possible only in deeply sedated mechanically ventilated patients with no spontaneous breathing. Alternative methods, including fluid 
challenges or passive leg raising, are therefore more widely applicable
10. We recommend individualizing the type of intravenous fluid administered. For example, albumin administration may be considered in an edema‑
tous patient with profound hypoalbuminemia or prolonged non‑response to crystalloids
11. We recommend monitoring of chloride levels if saline solutions are administered. Saline solutions should not be banned, but one must keep in 
mind that liberal administration of saline results in hyperchloremia, and this may result in a worsening metabolic acidosis and renal impairment
12. We recommend individualizing the initiation of vasopressor therapy. Fluid pre-loading may be considered in less severe cases, whereas fluid co‑
loading parallel to vasopressor initiation should be preferred in cases of life‑threatening hypotension or a low diastolic arterial pressure
13. We recommend individualizing arterial blood pressure levels. Although a mean value of 65 mmHg may be recommended as an initial goal, the 
optimal level may be higher in patients with a history of hypertension, atherosclerosis or chronic kidney disease. Conversely it may be lower in 
younger patients without previous vascular problems, in those with chronically low arterial pressure, or in whom adequate tissue perfusion is 
maintained
14. We recommend optimizing oxygen delivery, based on clinical assessment complemented by careful hemodynamic assessment including meas‑
urement of mixed (or central) venous oxygen saturation  (SvO2) and even carbon dioxide‑derived variables. A low  SvO2 in the presence of a normal 
 SaO2 indicates inadequate overall oxygen delivery to the tissues. More importantly, a normal or high  SvO2 does not exclude tissue hypoxia
15. We recommend a multimodal approach to assessing tissue perfusion, including mental status, urine output, peripheral perfusion, and blood 
lactate levels, taking into consideration the physiological reserve of the patient
16. We recommend individualizing blood transfusion. Transfusion should be based not only on measurements of hemoglobin concentration, but on 
clinical evaluation including persisting signs of tissue hypoperfusion, and measurements of  SvO2 and lactate
17. We recommend individualizing administration of inotropic agents when tissue hypoperfusion relates to impaired cardiac function (documented 
at least by echocardiography). The choice and the dose of the inotropic agent should be based on individual hemodynamic monitoring with 
repeated measurements
18. We recommend individualizing the decision to administer corticosteroids, not only for septic shock, but also for other conditions such as severe 
pneumonia and ARDS
19. We recommend involving senior colleagues and consultants, especially since guidelines are most useful for non‑experts. Team work, commu‑
nication and multidisciplinary teams are essential aspects. One of the most overarching recommendations is to seek for guidance from other 
colleagues and to clearly document the rationale for an intervention –be it recommended or not in the guidelines
20. We recommend carefully measuring and monitoring the effects of any therapeutic measures undertaken and deciding whether or not to continue 
or adjust treatment accordingly
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father of evidence-based medicine (EBM) stated, “Good 
doctors use both individual clinical expertise and the 
best available external evidence, and neither alone is 
enough. Without clinical expertise, practice risks becom-
ing tyrannised by evidence, for even excellent external 
evidence may be inapplicable to or inappropriate for an 
individual patient. Without current best evidence, prac-
tice risks becoming rapidly out-of-date, to the detriment 
of patients.” [9].
The conundrum is how to encourage guideline imple-
mentation yet at the same time promote personalized 
medicine. The new guidelines [2] offer little leeway for 
adapting the recommendations to the idiosyncrasies of 
each and every patient. Many of the recommendations 
attempt to fit most (if not all) of our patients. Sets of 
recommendations have been translated into bundles of 
care to be applied within a rigid time-frame to the “aver-
age” patient. This approach has sacrificed precision for 
homogenization and expediency. Some allowance for 
breaking the “one size fits all” guideline mold that has 
taken root in the last two decades would have been a dar-
ing but welcome and timely change.
We have therefore taken the liberty of putting forward 
some proposals of how guidelines could be adapted to 
individualize care (Table  1). We fully acknowledge that 
these recommendations are primarily based on patho-
physiological considerations and clinical experience 
rather than on RCT data.
The way forward is to be bold enough to question how 
we can do better. It may be time to move from a mass 
approach, based on pragmatic studies performed on het-
erogeneous populations, to tailored studies allowing both 
dissection and integration of the information collected 
in specific sepsis phenotypes. We need to embrace ther-
agnostic approaches, using biomarkers to identify only 
those patients for whom the intervention is suited, and 
to titrate dose and duration to optimal effect. Crucially, 
we need to restore the application of physiology and bio-
chemistry to the forefront of our clinical practice. Return-
ing to Sackett: “Evidence based medicine is not "cookbook" 
medicine. (…) External clinical evidence can inform, but 
can never replace, individual clinical expertise, and it is 
this expertise that decides whether the external evidence 
applies to the individual patient at all and, if so, how it 
should be integrated into a clinical decision.” [9]. Sepsis is 
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